Threshold Pharmaceuticals Inc

Type: Company
Name: Threshold Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.thresholdpharm.com/
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma

LONDONInvestor-Edge has initiated coverage on the following equities: Amicus Therapeutics Inc. (NASDAQ: FOLD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), and ... [Published Bio-Medicine - Oct 22 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Time To Plunge Into Stocks?

Heather Pelant, Managing Director of BlackRock comments, " An Investing Secret for When the Market Drops ":Back in August, I wrote a piece called “Why Cash is Not a Strategy.” I confessed then that like many people, I was sitting on more cash than I knew ... [Published Seeking Alpha - Oct 21 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Threshold Pharmaceuticals Hits New 12-Month Low at $2.82 (THLD)

Shares of Threshold Pharmaceuticals (NASDAQ:THLD) hit a new 52-week low during mid-day trading on Monday , AnalystRatingsNetwork.com reports. The stock traded as low as $2.82 and last traded at $3.05, with a volume of 515,322 shares changing hands. The ... [Published American Banking News - Forex - Oct 14 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 1 reports

Threshold Pharmaceuticals: New 52-Week Low Set Today (THLD)

Threshold Pharmaceuticals (NASDAQ:THLD) traded today at a new 52-week low of $3.11. This new low was reached on below average trading volume as 648,000 shares traded hands, while the average 30-day volume is approximately 984,000 shares. ... [Published Individual.com - Oct 08 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Recent 52-Week Low Surpassed in Shares of Threshold Pharmaceuticals (THLD)

(Financial News NetwFork O) Shares of Threshold Pharmaceuticals (NASDAQ:THLD) traded today at $3.30, breaking its 52-week low. Approximately 383,000 shares have changed hands today, as compared to an average 30-day volume of 981,000 shares. There is ... [Published Individual.com - Oct 07 2014]
First reported Oct 04 2014 - Updated Oct 04 2014 - 2 reports

Threshold Pharmaceuticals Director Sells $899,220 in Stock (THLD)

Threshold Pharmaceuticals (NASDAQ:THLD) Director Jeffrey W. Bird unloaded 238,520 shares of the company’s stock on the open market in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $3.77, for a total value of $899,220.40. ... [Published Mideast Time - Oct 04 2014]
First reported Sep 22 2014 - Updated Sep 23 2014 - 5 reports

Threshold down on Phase III data delay

Threshold Pharmaceuticals Inc. (NASDAQ:THLD) fell $0.50 (11%) to $3.97 on Monday after saying it expects delayed data from its Phase III trial of TH-302 to treat unresectable or metastatic soft tissue sarcoma (STS).The delay is based on the results o ... [Published BioPortfolio - Sep 23 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Healthcare Review: Genetic Technologies, Progenics Pharmaceuticals, Repros Therapeutics, Tekmira Pharmaceuticals, Threshold Pharmaceuticals

U.S. stocks fell on Monday, with the Dow Jones Industrial Average stepping back from an all-time high, as uncertainty about China's growth injected caution into global markets. Stocks' cautious tone began overnight, after China's financial minister said ... [Published BioMedReports - Sep 22 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw 16th Annual Global Investment Conference

SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 2, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Rodman & Renshaw 16th Annual ... [Published Marketwire - Breaking News Releases - Sep 02 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Biotech Stock Mailbag: Threshold, Galena, CytRx

BOSTON (TheStreet) -- Aalate summer Biotech Stock Mailbag. Sean L. writes: Big fan and follower of all things biotech. I came across the Feuerstein-RatainaRule. I don't doubt the validity or consistency of it, however, I'm wonderingadoes the rule hold ... [Published The Street Latest - Aug 22 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Threshold Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results

SOUTH SAN FRANCISCO, CA--(Marketwired - Aug 1, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the second quarter 2014. Revenue for the second quarter ended June 30, 2014 was $3.7 million. The operating loss ... [Published Marketwire - Breaking News Releases - Aug 01 2014]
First reported May 30 2014 - Updated May 30 2014 - 2 reports

Threshold Announces Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Recurrent Glioblastoma

CHICAGO, IL--(Marketwired - May 30, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)  ... [Published Marketwire - Breaking News Releases - May 30 2014]

Quotes

Second, Michael Gayed, co-CIO at Pension Partners , wrote a comment on why the real correction is to come, stating "the intermarket movement thus far has been reminiscent of the Summer Crash of 2011, though not as violent nor severe yet." (Make sure you read Michael and Charles Bilello's paper, An Intermarket Approach to Tactical Risk Rotation: Using the Signaling Power of Treasuries to...
The Fed is basically telling Europe's big banks: "Don't worry about Angela Merkel, Wolfgang Schäuble, and the lack of major QE from the ECB. If they don't act, we will act in a forceful manner allowing you to use our balance sheet to shore up yours."
...The Avastin basically creates the arena where the TH-302 does its best work, sparing the body's healthier cells. "So you don't hurt the bone marrow and the kidneys and the liver and other areas" that often suffer in chemotherapy treatments, Dr. Brenner said
...President and CEO Dr. Mark J Murray says, "Our TKM-Ebola drug supplies are limited, but we will continue to help where we can as we continue to focus on the other important objectives we have to advance therapies to meet the unmet needs of patients."

More Content

All (38) | News (25) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Market Momentum on Biotech Stocks - Amicus Ther... [Published Bio-Medicine - Oct 22 2014]
Market Momentum on Biotech Stocks - Amicus Ther... [Published Financial Services - Oct 22 2014]
Oncology, palliative care partnership reduced p... [Published Orthopedics Today - Oct 22 2014]
Time To Plunge Into Stocks? [Published Seeking Alpha - Oct 21 2014]
Fed Prepping Markets For More QE? [Published Seeking Alpha - Oct 19 2014]
Threshold Pharmaceuticals Hits New 12-Month Low... [Published American Banking News - Forex - Oct 14 2014]
What's Up With This Crazy Stock Market? [Published Seeking Alpha - Oct 13 2014]
Threshold Pharmaceuticals: New 52-Week Low Set ... [Published Individual.com - Oct 08 2014]
Recent 52-Week Low Surpassed in Shares of Thres... [Published Individual.com - Oct 07 2014]
Threshold Pharmaceuticals Director Sells $899,2... [Published Mideast Time - Oct 04 2014]
Threshold Pharmaceuticals major shareholder Hil... [Published American Banking News - Oct 04 2014]
CTRC doctor wins $1.6 million FDA orphan grant ... [Published EurekAlert! - Oct 03 2014]
EMD Serono - The Culture Of Specialty Care [Published Life Science Leader - Oct 02 2014]
Pyruvate Induces Transient Tumor Hypoxia by Enh... [Published Plosone.org - Sep 25 2014]
TH-302 demonstrates encouraging activity in sof... [Published Orthopedics Today - Sep 23 2014]
Threshold down on Phase III data delay [Published BioPortfolio - Sep 23 2014]
Threshold drug moves forward on cancer trial bu... [Published San Francisco Business Times - Sep 22 2014]
Healthcare Review: Genetic Technologies, Progen... [Published BioMedReports - Sep 22 2014]
Threshold Pharma Says Phase 3 Trial of TH-302 i... [Published Austin American Statesman - Sep 22 2014]
Threshold Pharma Says Phase 3 Trial of TH-302 i... [Published Benzinga.com - Sep 22 2014]
Threshold Pharmaceuticals Announces Its Phase 3... [Published Marketwire - Breaking News Releases - Sep 22 2014]
Threshold Pharmaceuticals Announces Presentatio... [Published Marketwire - Breaking News Releases - Sep 02 2014]
BioNews [8.29.14] [Published eClinical Trends - Aug 29 2014]
Biotech Stock Mailbag: Threshold, Galena, CytRx [Published The Street Latest - Aug 22 2014]
5 Stocks Ready for Breakouts [Published The Street Latest - Aug 11 2014]
4 Biotech Stocks Under $10 to Trade for Breakouts [Published The Street Latest - Aug 01 2014]
Threshold Pharmaceuticals Reports Second Quarte... [Published Marketwire - Breaking News Releases - Aug 01 2014]
Threshold Announces Initiation of Dosing With T... [Published Marketwire - Breaking News Releases - Jul 09 2014]
Threshold Pharmaceuticals Initiates 440-Patient... [Published Marketwire - Breaking News Releases - Jul 01 2014]
Pancreatic Ductal Adenocarcinoma Pipeline Revi... [Published BioPortfolio - Jun 24 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Threshold Pharmaceuticals Announces Its Phase 3... [Published Marketwire - Breaking News Releases - Sep 22 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 22, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the Independent Data Monitoring Committee (IDMC) has completed the planned interim efficacy and safety analyses of unblinded ...
Threshold Pharmaceuticals Announces Presentatio... [Published Marketwire - Breaking News Releases - Sep 02 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 2, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Rodman & Renshaw 16th Annual ...
BioNews [8.29.14] [Published eClinical Trends - Aug 29 2014]
Top News HeadlineCompanyType Band of West Coast biotech insiders pushes oral anticoagulant to PhIII Armetheon, Inc.Study Gilead Sciences, Inc., "The New Genentech," Remaps Massive Foster City Campus Gilead Sciences, Inc.Expanding Offic ...
Threshold Pharmaceuticals Reports Second Quarte... [Published Marketwire - Breaking News Releases - Aug 01 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Aug 1, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the second quarter 2014. Revenue for the second quarter ended June 30, 2014 was $3.7 million. The operating loss ...
Threshold Announces Initiation of Dosing With T... [Published Marketwire - Breaking News Releases - Jul 09 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 9, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, ...
1 2 3

Press Releases

sort by: Date | Relevance
Market Momentum on Biotech Stocks - Amicus Ther... [Published Financial Services - Oct 22 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.